Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BIOA
SELLBioAge Labs, Inc. · Healthcare · United States · $968M · Avg Vol: $15M/d
COMPANY DESCRIPTION
BioAge Labs is a biotechnology company focused on developing therapeutics to treat age-related diseases and extend healthy human lifespan, using a proprietary platform to identify novel drug targets. Its competitive advantage is a pioneering approach to aging biology, leveraging extensive human data and AI-driven drug discovery to target fundamental aging mechanisms. BioAge is a niche biopharmaceutical company in the emerging field of longevity medicine, with a high-risk, high-reward pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9.0M | — | 10.3M | 54.3M | 36.0M | 99.9% |
| EPS | -23.76 | -3.17 | -6.63 | -2.24 | — | -2.35 | -2.48 | -2.04 | — |
| Shares | 34.2M | 34.2M | 35.9M | 37.4M | +9.4% | 44.5M | — | — | — |
| Debt | 2.5M | 53.3M | 8.7M | 5.6M | 31.1% | 4.0M | — | — | — |
| Equity | -112.6M | -173.4M | 323.1M | 272.1M | -15.8% | — | — | — | — |
| Op CF | -36.2M | -37.4M | -51.5M | -81.6M | — | -88.3M | — | — | — |
| Inv CF | -0.1M | -0.3M | -0.4M | -95.2M | — | — | — | — | — |
| Fin CF | 2.5M | 34.9M | 381.2M | 11.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BIOA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BIOA | BioAge Labs, Inc.(you) | $968M | 32 | SELL |
| ESPR | Esperion Therapeutics, Inc. | $817M | 34 | SELL |
| GLAS | Glass House Brands Inc. | $899M | 36 | HOLD |
| HROW | Harrow, Inc. | $1.5B | 36 | HOLD |
| VREO.CN | Vireo Growth Inc. | $500M | 36 | HOLD |
| AMLX | Amylyx Pharmaceuticals, Inc. | $2.0B | 27 | SELL |
| AKBA | Akebia Therapeutics, Inc. | $327M | 30 | SELL |
| EOLS | Evolus, Inc. | $394M | 38 | HOLD |
| ORGO | Organogenesis Holdings Inc. | $308M | 38 | HOLD |
| AQST | Aquestive Therapeutics, Inc. | $462M | 18 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%